C4 Therapeutics Inc

For the period ended Oct 31, 2024. Filed Oct 31, 2024.

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

Oct 31, 2024 · Filed Oct 31, 2024

Use the contents to explore the available documents and sections.

CCCC$3.10+5.1%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

EX-99.1 · CFT1946:

CFT1946:

Initiate the Phase 1b dose escalation cohort evaluating CFT1946 in combination with trametinib in melanoma by year-end.

Present data from multiple anticipated readouts in 2025, including:

Full monotherapy CFT1946 dose escalation cohorts in BRAF V600 mutant solid tumors.

Expansion cohorts evaluating CFT1946 as a monotherapy in melanoma.

Phase 1b dose escalation cohort evaluating CFT1946 in combination with cetuximab in CRC.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.